secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-197017
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx Q2 net loss $27.2M; earns $68M milestone from Kite; IND cleared for myasthenia gravis
--------------------------------------------------------------------------------

- Earned $68M milestone from Kite for iMMagine-1 enrollment in multiple myeloma.
- Cash, equivalents, and marketable securities $646.8M as of June 30, 2024; funds operations into 2027.
- Collaboration revenue $27.4M (up from $14.3M YoY); net loss $27.2M vs $23.9M YoY.
- FDA cleared anito-cel IND for myasthenia gravis, a chronic autoimmune disease; wholly owned by Arcellx.
- Kite initiated global Phase 3 iMMagine-3; abstract submitted for ASH Annual Meeting by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312524197017/0001193125-24-197017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312524197017/d874563d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-197017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer